ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

@article{Gobbi2005ABVDVM,
  title={ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.},
  author={P. Gobbi and A. Levis and T. Chisesi and C. Broglia and U. Vitolo and C. Stelitano and V. Pavone and L. Cavanna and G. Santini and F. Merli and M. Liberati and L. Baldini and G. L. Deliliers and E. Angelucci and R. Bordonaro and M. Federico},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 36},
  pages={
          9198-207
        }
}
  • P. Gobbi, A. Levis, +13 authors M. Federico
  • Published 2005
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE In this multicenter, prospective, randomized clinical trial on advanced Hodgkin's lymphoma (HL), the efficacy and toxicity of two chemotherapy regimens, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone (Stanford V) and mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine (MOPPEBVCAD), were compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD… Expand
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
  • T. Chisesi, M. Bellei, +13 authors M. Federico
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
The long-term analysis confirmed ABVD and MEC superiority to StV and the use of RT after StV was established as mandatory. Expand
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
  • M. Federico, S. Luminari, +16 authors P. Gobbi
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
BEACOPP is associated with a significantly improved PFS compared with ABVD, with a predictable higher acute toxicity, and was associated with higher rates of severe infections than ABVD and CEC. Expand
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
  • P. Hoskin, L. Lowry, +13 authors P. Johnson
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
In a large, randomized trial, the efficacies of Stanford V and ABVD were comparable when given in combination with appropriate radiotherapy. Expand
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
  • L. Gordon, F. Hong, +15 authors S. Horning
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
ABVD remains the standard of care for patients with advanced Hodgkin lymphoma, with complete remission and clinical complete remission rates of 73% for ABVD and 69% for Stanford V. Expand
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
  • P. Carde, M. Karrasch, +17 authors N. Mounier
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
ABVD8 and BEACopP4+4 resulted in similar EFS and OS in patients with high-risk advanced-stage HL, but BEACOPP4-4 did not demonstrate a favorable effectiveness or toxicity ratio compared with ABVD8, treatment burden, immediate and late toxicities, and associated costs must be considered. Expand
The chemotherapy/radiation balance in advanced Hodgkin's lymphoma: overweight which side?
  • P. Carde
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
The article by Gobbi et al aimed to investigate which of three chemotherapy regimens was superior by itself; that is, which regimen allowed a less frequent usage of irradiation, and when radiation was used, allowed a greater limitation of the irradiation field extent than in the original chemotherapy/radiotherapy combinations. Expand
Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519).
TLDR
Patients who received consolidation RT apparently had better outcomes, consistently across all prognostic groups which persisted in multivariate analysis, suggesting that RT contributes significantly to the cure rate for advanced HL, although patient selection for combined modality treatment requires better definition in prospective trials. Expand
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
TLDR
The overall risk of performance and detection bias was low for overall survival (OS), but was high for other outcomes, as therapy blinding was not feasible. Expand
XVII. Treatment of advanced‐stage Hodgkin lymphoma
TLDR
The next generation of clinical trials included hybrid regimens such as MOPP/ABVD, cyclophosphamide, oncovin, procarbazine and prednisone (COPP)/ABVD or MOPp/ABV or regimens containing even more drugs in rapidly alternating sequence (Table 1). Expand
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
TLDR
This meta-analysis showed that adult patients between 16 and 60 years of age with early unfavourable or advanced stage HL benefited from chemotherapy including escalated BEACOPP regarding PFS, but there was no significant difference in OS. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
  • J. Connors, P. Klimo, +13 authors B. Zee
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
MOPp/ABV hybrid and alternating MOPP/ABVD regimens are equally effective for patients with advanced Hodgkin's disease. Expand
MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.
TLDR
In addition to the excellent response rate, the results were reached through abbreviation, intensification, and hybridization of an existing alternating regimen, and RT had limited use in this program, which may have contributed to lowering the risk of second tumors. Expand
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
TLDR
ABVD and the MOPP/ABV hybrid are effective therapies for Hodgkin's disease and ABVD should be considered the standard regimen for treatment of advanced Hodgkin’s disease. Expand
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
TLDR
Investigation of three combinations of chemotherapy for advanced Hodgkin's disease found increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD and standard BEACopP. Expand
Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
TLDR
The higher cumulative and single drug DI recorded with MOPPEBVCyED may reflect better short-term tolerability, but it does not lead to better disease control, and its late toxicity may be expected to be lower in the future. Expand
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
TLDR
ABVD therapy for 6 to 8 months was as effective as 12 months of MopP alternating with ABVD, and both were superior to MOPP alone in the treatment of advanced Hodgkin's disease. Expand
Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.
TLDR
The EVA regimen appears to have an overall survival outcome comparable to ABVD, but without the lung toxicity, and the high salvage rate of second-line therapy, in most instances at conventional dosage, suggests an absence of cross-resistance to alkylating agents in patients treated with EVA. Expand
Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease.
TLDR
MOPPEBVCAD with selected radiotherapy is a highly effective regimen in advanced Hodgkin's disease and early and late toxicity are no more severe than what would be expected with other alternating or hybrid regimens. Expand
Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
TLDR
Preliminary results indicate that the Stanford V chemotherapy regimen with or without RT is well-tolerated and effective therapy for bulky, limited-stage, and advanced-stage Hodgkin's disease. Expand
Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.
TLDR
This intensive regimen, which does not routinely require the support of hematopoietic growth factors and can be delivered in an outpatient setting, warrants a prospective comparison in a randomized trial versus one of the more effective standard-combination regimens. Expand
...
1
2
3
4
...